Loading
Life sciences · Journal article
Journal of Nanobiotechnology · September 15, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Targeted delivery to injured glomerular endothelial cells remains a major challenge in diabetic kidney disease (DKD) because systemically administered therapeutics are limited by rapid kidney clearance, complex glomerular vascular architecture, and limited endothelial retention. Biomimetic red blood cell (RBC) membrane-hybrid lipid nanoparticles offer a promising strategy to improve vascular compatibility, prolong circulation, and protect therapeutic cargos. However, the application of this biomimetic platform for glomerular endothelial cell-targeted delivery of dCas9-based CRISPR activation (CRISPRa) ribonucleoprotein (RNP) complexes has not been established. dCas9-sgRNA RNP complexes were efficiently incorporated into RBC-hybrid lipid nanoparticles through charge-mediated assembly using an ionizable lipid. The resulting VE-PTP-targeted RBC/LNP-Ab nanoparticles showed stable nanoscale size, favorable surface charge modulation, efficient RNP loading, and structural features consistent with RBC membrane-hybrid nanoparticle formation. In VE-PTP-upregulated endothelial cells under DKD-mimicking conditions, the nanoparticles enhanced intracellular dCas9 delivery and increased endogenous ANG1 expression, restoring the ANG1/ANG2 balance and downstream Tie2-Akt signaling. Following systemic administration in advanced DKD mice, VE-PTP-targeted RBC-hybrid nanoparticles preferentially localized to glomerular endothelial cells, increased ANG1 expression in the diabetic kidney, reduced albuminuria, and attenuated structural kidney injury. These results demonstrate that VE-PTP-targeted RBC-hybrid nanoparticles can serve as a biomimetic non-viral platform for glomerular endothelial cell-targeted CRISPRa RNP delivery. This strategy provides proof-of-concept for disease-specific transcriptional gene modulation in DKD and may provide a framework for targeted endothelial therapy in other microvascular diseases.